Dulaglutide injection for type 2 diabetes and cardiovascular risk reduction

Dulaglutide is a once-weekly injectable medication used alongside diet and exercise to improve blood sugar control in adults and children aged 10 years and older with type 2 diabetes mellitus. It also helps reduce the risk of major cardiovascular events in adults with type 2 diabetes who have cardiovascular disease or multiple risk factors.

Dulaglutide is approved for:

• Adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control.
• Adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors, to reduce the risk of major adverse cardiovascular events such as cardiovascular death, non-fatal heart attack, or non-fatal stroke.

Limitations:

• Not studied in patients with a history of pancreatitis; consider alternative therapies in these cases.
• Not indicated for type 1 diabetes mellitus.
• Not recommended for patients with severe gastrointestinal disease, including severe gastroparesis.

Dulaglutide

Dulaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, which mimics the action of the natural hormone GLP-1. It activates GLP-1 receptors to enhance glucose-dependent insulin secretion, suppress inappropriate glucagon release, slow gastric emptying, and reduce appetite. These effects contribute to lowering blood sugar levels and improving glycemic control in patients with type 2 diabetes.

Adults

• Start with 0.75 mg injected subcutaneously once weekly.
• If additional glycemic control is needed, increase to 1.5 mg once weekly after at least 4 weeks on initial dose.
• If further control is necessary, dosage can be increased by 1.5 mg increments every 4 weeks, up to a maximum of 4.5 mg once weekly.

Pediatric patients (10 years and older)

• Start with 0.75 mg injected subcutaneously once weekly.
• If needed, increase to a maximum of 1.5 mg once weekly after at least 4 weeks on initial dose.

Administration instructions

• Administer once weekly by subcutaneous injection in the abdomen, thigh, or upper arm.
• Injection time can be any time of day, with or without food.
• Rotate injection sites with each dose.
• When used with insulin, give injections separately and not mixed; injections may be in the same body region but not adjacent.
• If a dose is missed, administer it as soon as possible if at least 3 days (72 hours) remain before the next dose. If fewer than 3 days remain, skip the missed dose and continue the regular schedule.
• The day of weekly administration can be changed, provided the last dose was given 3 or more days before the new injection day.
• Ensure patients and caregivers are trained on proper injection technique before starting treatment.

• Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• History of serious hypersensitivity reaction to dulaglutide or any component of the product.

Thyroid C-cell Tumors

Dulaglutide caused dose- and duration-dependent thyroid C-cell tumors (adenomas and carcinomas) in rats after lifetime exposure. The relevance to humans is unknown. Dulaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Patients should be counseled on the potential risk and symptoms of thyroid tumors such as neck mass, difficulty swallowing, breathing problems, or persistent hoarseness. Routine monitoring with serum calcitonin or thyroid ultrasound is of uncertain value.

Pancreatitis

Cases of pancreatitis have been reported in clinical trials and postmarketing. If pancreatitis is suspected, discontinue dulaglutide promptly and do not restart if confirmed. Use caution in patients with a history of pancreatitis.

Hypoglycemia

Risk increases when used with insulin secretagogues (like sulfonylureas) or insulin. Dose reduction of these agents may be needed to reduce hypoglycemia risk. Patients should be informed of hypoglycemia signs.

Hypersensitivity Reactions

Serious hypersensitivity including anaphylaxis and angioedema may occur. If reactions develop, discontinue dulaglutide and treat urgently.

Acute Kidney Injury

Renal impairment or acute kidney injury has been reported, often associated with dehydration from gastrointestinal side effects. Monitor kidney function in patients with renal impairment experiencing severe GI symptoms.

Severe Gastrointestinal Disease

Dulaglutide can cause gastrointestinal adverse effects and is not recommended for patients with severe gastrointestinal disease including severe gastroparesis.

Diabetic Retinopathy

Complications have been reported in patients with a history of diabetic retinopathy. Monitor patients at risk, especially during rapid glucose control improvements.

Gallbladder Disease

Events like cholelithiasis and cholecystitis have been reported. If suspected, conduct gallbladder studies and follow-up.

Common Adverse Reactions (≥5%)

• Nausea
• Diarrhea
• Vomiting
• Abdominal pain
• Decreased appetite
• Dyspepsia
• Fatigue

Additional Gastrointestinal Reactions

• Constipation
• Flatulence
• Abdominal distension
• Gastroesophageal reflux disease
• Eructation (belching)

Other Adverse Reactions

• Injection-site reactions (rash, erythema) – more common in pediatric patients
• Hypoglycemia (especially when used with insulin or insulin secretagogues)
• Sinus tachycardia and mild mean heart rate increase (2–4 bpm)
• First-degree atrioventricular (AV) block and PR interval prolongation
• Elevation of pancreatic enzymes (amylase and lipase)
• Serious hypersensitivity reactions including anaphylaxis and angioedema (rare)
• Acute kidney injury and worsening renal failure (rare postmarketing reports)
• Gallbladder disease including cholelithiasis and cholecystitis

• Dulaglutide delays gastric emptying, potentially reducing the absorption rate of coadministered oral medications, especially those with a narrow therapeutic index such as warfarin. Monitor drug levels carefully when used together.
• When initiating dulaglutide in patients taking insulin secretagogues (e.g. sulfonylureas) or insulin, consider reducing the dose of these agents to lower hypoglycemia risk.

Pregnancy

Limited human data are available. Animal studies showed adverse effects including fetal abnormalities and embryonic death at exposures multiple times higher than human doses. Use only if potential benefit justifies the risk.

Breastfeeding

It is unknown if dulaglutide is present in human milk. No animal data on excretion in milk. Consider benefits of breastfeeding against the mother's clinical need for dulaglutide and potential risks to the infant.